Last $1.50 USD
Change Today -0.13 / -7.98%
Volume 18.4M
IBIO On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

ibio inc (IBIO) Snapshot

Open
$1.81
Previous Close
$1.63
Day High
$1.93
Day Low
$1.47
52 Week High
10/17/14 - $3.48
52 Week Low
05/27/14 - $0.24
Market Cap
101.2M
Average Volume 10 Days
28.3M
EPS TTM
$-0.06
Shares Outstanding
67.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IBIO INC (IBIO)

Related News

No related news articles were found.

ibio inc (IBIO) Related Businessweek News

No Related Businessweek News Found

ibio inc (IBIO) Details

iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that enhances the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates comprise IBIO-CFB03, a product for treatment of idiopathic pulmonary fibrosis; C1 Esterase Inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement protein; and Palivizumab, a monoclonal antibody for the therapeutic protein market. Its vaccine products include H1N1 Influenza and H5N1 Influenza products that have completed Phase I human clinical trials, as well as yellow fever vaccine; malaria and hookworm parasitic pathogen vaccines; and human papillomavirus therapeutic vaccine. The company’s product candidates also comprise Anthrax/Plague bacterial disease vaccine; and Anthrax, a monoclonal antibody for the biodefense market. It has strategic alliances and collaborations with various companies, such as Fraunhofer Center for Molecular Biology, GE Healthcare, FioCruz, and Caliber Biotherapeutics LLC. The company is headquartered in Newark, Delaware.

7 Employees
Last Reported Date: 09/29/14

ibio inc (IBIO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $300.0K
President
Total Annual Compensation: $230.0K
Chief Scientific Officer
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2013.

ibio inc (IBIO) Key Developments

The Rosen Law Firm Files Class Action Lawsuit Against iBio, Inc

The Rosen Law Firm announced that it has filed a class action lawsuit against iBio, Inc. on behalf of all purchasers of the company's common stock between October 13, 2014 and October 23, 2014, inclusive. The lawsuit seeks to recover damages for iBio shareholders under the federal securities laws. The suit is pending in U.S. District Court for the District of Delaware. The lawsuit claims that iBio issued materially false and misleading statements to investors by wrongfully suggesting that iBio's Launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug, ZMapp. The lawsuit claims that when the true facts were revealed, the price of iBio's stock dropped, damaging investors.

iBio, Inc. Expands Exclusive Product Collaboration With Novici Biotech LLC

iBio, Inc. and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products, to include iBio's proprietary IBIO-CFB03 product for idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases. This expanded program will combine the strength of the iBioLaunch(TM) platform with Novici's patented GRAMMR(R) technology for rapid evolution of gene sequences to significantly increase expression yield of target proteins. IBIO-CFB03 and related proteins have been produced in plants on the iBioLaunch platform substantially more quickly and cost-effectively than has been possible with traditional methods. By combining the strengths of the iBioLaunch platform with Novici's GRAMMR technology, iBio expects to drive production efficiency even further as the fibrosis team initiates expanded animal testing and additional IND-enabling tasks.

Thomas A. Medsger Joins iBio, Inc.'s Clinical Advisory Board

iBio, Inc. has appointed Thomas A. Medsger Jr., M.D., to its clinical advisory board. Dr. Medsger is an expert in systemic sclerosis and localized scleroderma. Dr. Medsger will provide iBio with guidance on the further development and commercialization of the company's novel drug candidate, IBIO-CFB03, for idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and other fibrotic diseases.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBIO:US $1.50 USD -0.13

IBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IBIO.
View Industry Companies
 

Industry Analysis

IBIO

Industry Average

Valuation IBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 480.2x
Price/Book 16.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 476.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IBIO INC, please visit www.ibioinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.